MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
OptimizeRx Corporation Book Value 2011-2026 | OPRX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OptimizeRx Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 M | 126 M | 131 M | 50 M | 44.9 M | 18.5 M | 6.22 M | 7.81 M | 8.94 M | 4.61 M | 2.04 M | 1.5 M | 1.59 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 131 M | 1.5 M | 40.8 M |
Quarterly Book Value OptimizeRx Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122 M | 119 M | 116 M | 117 M | 114 M | 121 M | 123 M | 127 M | 116 M | 116 M | 124 M | 126 M | 130 M | 141 M | 131 M | 131 M | 127 M | 125 M | 122 M | 50 M | 50 M | 50 M | 50 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 6.22 M | 9.76 M | 9.76 M | 9.76 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 7.03 M | 7.03 M | 7.03 M | 7.03 M | 3.95 M | 4.01 M | 4.01 M | 4.01 M | 2.18 M | 2.18 M | 2.18 M | 2.18 M | 1.59 M | 2.15 M | 1.03 M | 2.89 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 141 M | 1.03 M | 50.7 M |
Book Value of other stocks in the Health information services industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
391 M | - | 0.29 % | $ 206 M |  USA |
 |
Cerner Corporation
CERN
|
3.68 B | - | - | $ 27.9 B | USA |
 |
Computer Programs and Systems
CPSI
|
187 M | - | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
1.53 B | - | - | $ 2.94 B | USA |
 |
Change Healthcare
CHNG
|
3.28 B | - | - | $ 9.03 B | USA |
 |
Castlight Health, Inc.
CSLT
|
7.25 B | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
715 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
26.4 M | - | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
28.7 M | - | - | $ 102 M | USA |
 |
Evolent Health
EVH
|
859 M | $ 2.77 | 10.36 % | $ 260 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.41 B | - | -10.39 % | $ 886 M | USA |
 |
GoodRx Holdings
GDRX
|
725 M | $ 2.3 | 3.14 % | $ 887 M | USA |
 |
MTBC
MTBC
|
59.5 M | - | -0.58 % | $ 51.7 M | USA |
 |
Akerna Corp.
KERN
|
666 M | - | - | $ 161 M | USA |
 |
NextGen Healthcare
NXGN
|
432 M | - | - | $ 1.6 B | USA |
 |
10x Genomics
TXG
|
741 M | $ 25.29 | 1.98 % | $ 2.96 B | USA |
 |
1Life Healthcare
ONEM
|
1.73 B | - | - | $ 3.37 B | USA |
 |
Health Catalyst
HCAT
|
246 M | $ 1.21 | 8.04 % | $ 84.6 M | USA |
 |
HealthEquity
HQY
|
2.11 B | $ 83.16 | 2.21 % | $ 7.16 B | USA |
 |
Premier
PINC
|
1.53 B | - | - | $ 2.33 B | USA |
 |
Schrödinger
SDGR
|
364 M | $ 12.4 | 4.11 % | $ 911 M | USA |
 |
Phreesia
PHR
|
337 M | $ 9.08 | 5.46 % | $ 542 M | USA |
 |
R1 RCM
RCM
|
347 M | - | - | $ 3.81 B | USA |
 |
Teladoc Health
TDOC
|
1.39 B | $ 5.52 | 5.15 % | $ 973 M | USA |
 |
Signify Health
SGFY
|
821 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
12.3 M | - | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
-225 M | - | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
7.15 M | - | - | $ 7.71 M | USA |
 |
American Well Corporation
AMWL
|
248 M | $ 6.24 | 14.39 % | $ 100 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-57 M | - | - | $ 255 M | USA |
 |
HealthStream
HSTM
|
511 M | $ 20.8 | 2.26 % | $ 632 M | USA |
 |
Omnicell
OMCL
|
1.24 B | $ 37.21 | 2.41 % | $ 1.71 B | USA |
 |
Progyny
PGNY
|
422 M | $ 17.25 | 0.44 % | $ 1.48 B | USA |
 |
So-Young International
SY
|
1.96 B | $ 2.74 | -0.72 % | $ 218 M |  China |
 |
Veeva Systems
VEEV
|
7.21 B | $ 167.5 | 5.32 % | $ 27.4 B | USA |
 |
Zhongchao
ZCMD
|
22.6 M | $ 1.96 | - | $ 6.7 M | China |